Charles Kelly, DO
Family Medicine · Fulton, MSNPI 1104895267
Payments from drug & device makers
Across 375 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$866
- Novo Nordisk$864
- Amgen$581
- Lilly USA, LLC$435
- Pfizer$407
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$346
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,749100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 50 | $866 |
| Novo Nordisk | 67 | $864 |
| Amgen | 41 | $581 |
| Lilly USA, LLC | 28 | $435 |
| Pfizer | 27 | $407 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $346 |
| Boehringer Ingelheim | 15 | $248 |
| GSK | 17 | $235 |
| AbbVie(2 entities) | 14 | $216 |
| Bayer | 12 | $206 |
| Otsuka America Pharmaceutical, Inc. | 8 | $203 |
| AstraZeneca | 12 | $174 |
| Xeris Pharmaceuticals, Inc. | 6 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $125 |
| E.r. Squibb & Sons, L.L.C. | 7 | $114 |
| Daiichi Sankyo Inc. | 4 | $80 |
| Astellas Pharma US Inc | 5 | $77 |
| Johnson & Johnson | 5 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $69 |
| Amarin Pharma, Inc. | 2 | $46 |
| Lundbeck LLC | 1 | $35 |
| Ironwood Pharmaceuticals, Inc | 2 | $31 |
| Ardelyx, Inc. | 1 | $28 |
| Abbott | 1 | $20 |
| Bausch Health US, LLC | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 2 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Novartis | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Strongbridge US Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$5,757 in reported general payments places this provider in the 85th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $149,606 |
| EliquisApixaban | 108 | $110,768 |
| JardianceEmpagliflozin | 59 | $70,290 |
| MounjaroTirzepatide | 49 | $56,736 |
| JanuviaSitagliptin Phosphate | 44 | $47,414 |
| FarxigaDapagliflozin Propanediol | 41 | $43,041 |
| XareltoRivaroxaban | 40 | $38,162 |
| TrulicityDulaglutide | 36 | $35,562 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $30,708 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $23,374 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $20,693 |
| MyrbetriqMirabegron | 23 | $18,628 |
| LinzessLinaclotide | 27 | $18,361 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $17,227 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $10,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $864 | $149,606139 claims |
| PfizerEliquis | $407 | $110,768108 claims |
| Lilly USA, LLCMounjaro, Trulicity | $435 | $92,29885 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr | $248 | $88,47693 claims |
| AstraZenecaFarxiga | $174 | $43,04141 claims |
| Johnson & JohnsonXarelto | $73 | $38,16240 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $235 | $30,71250 claims |
| AbbVieLinzess, Synthroid | $216 | $20,76755 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $18,62823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Fulton
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.